Insulin action in the hypothalamus results in the suppression of hepatic glucose production (HGP). Obesity is often associated with a diminished response to insulin, leading to impaired suppression of HGP in obese mice. Here, we demonstrate that blocking central leptin signaling in diet-induced obese (DIO) mice restores the liver's ability to suppress glucose production. Leptin increases the expression of the insulin receptor phosphatase PTP1B, which is highly expressed in the hypothalamus of DIO mice. We demonstrate that the central pharmacological inhibition or ARH-targeted deletion of PTP1B restores the suppression of HGP in obese mice. Additionally, mice that lack PTP1B in AgRP neurons exhibit enhanced ARH insulin signaling and have improved glucose tolerance and insulin sensitivity. Overall, our findings indicate that obesity-induced increases in PTP1B diminish insulin action in the hypothalamus, resulting in unconstrained HGP and contributing to hyperglycemia in obesity.
INTRODUCTION
Leptin is a hormone released from adipose tissue in proportion to adiposity level Zhang et al., 1994) . From the circulation, leptin enters the brain (Balland et al., 2014; Banks et al., 1996) and signals via its leptin receptor (LepRb), which is widely distributed throughout the brain with particularly high expression within the arcuate nucleus of the hypothalamus (ARH) (Scott et al., 2009; Tartaglia et al., 1995) , to attenuate food intake and decrease body weight (Friedman and Halaas, 1998; Halaas et al., 1995) . Importantly, obesity is characterized by hyperleptinemia and an inadequate response to this high level of endogenous leptin (Frederich et al., 1995) . For a long time, DIO mice were considered to be resistant to leptin, but there is increasing evidence suggesting otherwise. At the cellular level, DIO mice display leptin signaling in ARH neurons under basal conditions, as revealed by STAT3 phosphorylation, consistent with the presence of a response to endogenous leptin in obese mice (Balland and Cowley, 2017; Balland et al., 2014) . This observation is further supported by physiological evidence of leptin action in DIO mice because antagonizing leptin signaling results in increased food intake and body weight in DIO mice (Ottaway et al., 2015) . Besides its weight-regulating effect, leptin is also implicated in glucose homeostasis (Elmquist et al., 2005; Gutié rrez-Juá rez et al., 2004) . Obesity is associated with hyperleptinemia, hyperglycemia, hyperinsulinemia, and type 2 diabetes. Although insulin exerts a profound effect on the regulation of blood glucose in the periphery, the central activation of insulin receptor (InsR) is also required to maintain glucose homeostasis (Br€ uning et al., 2000) . Importantly, leptin and insulin share the same neuronal targets in the hypothalamus (Belgardt and Br€ uning, 2010; Garcia-Galiano et al., 2017) , and the co-activation of both signaling pathways within the same ARH neurons have important implications in energy metabolism .
In the present study, we provide in vivo evidence that blocking central leptin signaling facilitates hypothalamic insulin signaling and restores the suppression of hepatic glucose production (HGP) in DIO mice. Mechanistically, we show that protein tyrosine phosphatase 1B (PTP1B) represses the central insulin action on liver to control HGP. Pharmacological inhibition or genetic deletion of PTP1B in the ARH has similar metabolic improvements to LepRb antagonism in DIO mice. In addition, we show genetic evidence that these events are likely to occur in AgRP neurons. Altogether, our data indicate that leptin signaling in DIO mice is responsible for alterations in insulin-dependent central mechanisms involved in glucose homeostasis. These studies redefine our current understanding of central leptin action or resistance in obesity and highlight a previously unexplored mechanism by which leptin perturbs the central control of glucose metabolism in diet-induced obesity.
RESULTS

Central Inhibition of Leptin Signaling in DIO Mice Improves Glucose Tolerance and Hepatic Insulin Sensitivity
To test whether the central leptin signaling interferes with insulin action in DIO mice, we injected control and DIO mice intracerebroventricularly (i.c.v.) with leptin antagonist (LAN) , to block endogenous leptin from activating LepRb-associated signaling pathways in the brain, prior to subjecting mice to hyperinsulinemic-euglycemic clamps (Figure 1) . Hypothalamic insulin has previously been shown to inhibit HGP in rats (Obici et al., 2002; Pocai et al., 2005a) We also used the insulin receptor antagonist S961 (Vikram and Jena, 2010) , delivered i.c.v., to determine whether the physiological effect exerted by LAN requires insulin signaling. LAN pre-treatment did not change body weight of either control ( Figure S1H ) or DIO mice ( Figure S1A ). Interestingly, DIO mice treated with LAN required a higher glucose infusion rate (GIR) to maintain euglycemia when compared to aCSF-treated group ( Figures 1C-1E ). In parallel, HGP during the clamp was significantly reduced in the LAN group ( Figures 1F and S1B ). The glucose disposal rate (GDR) was not affected in the basal state, albeit a marked decrease in GDR was observed in the clamped mice treated with S961 and LAN + S961 ( Figure 1G ). Interestingly, the LAN-dependent improvements in GIR and HGP were completely blunted by the co-administration of insulin receptor antagonist S961 i.c.v. (Figures 1C, 1E , and 1F). Of note, blocking central LepRb signaling prior to hyperinsulinemiceuglycemic clamps perturbed normal glucose homeostasis in lean control mice (Figures S1D-S1I). Specifically, GIR and GDR were significantly reduced in control mice during the clamp (Figures S1F and S1G). This was accompanied by a marked increase in HGP ( Figure S1I) . Central Pharmacological Inhibition or ARH-Targeted Deletion of PTP1B Recapitulates the LAN-Dependent Restoration of Hypothalamic Insulin Signaling and Improves the Hepatic Response to Insulin in DIO Mice PTP1B is a negative regulator of leptin and insulin signaling (Bence et al., 2006; Elchebly et al., 1999; Galic et al., 2005; Goldstein et al., 1998; Zabolotny et al., 2002; Zhang et al., 2015) . Previous studies have shown that hypothalamic PTP1B is elevated in obesity (Dodd et al., 2017; Wu et al., 2005; Zabolotny et al., 2008; Zhang et al., 2015) and that leptin can promote PTP1B expression as part of a negative feedback loop (White et al., 2009) . We tested whether the sustained activation of LepRb signaling in obesity was coupled to an increased in PTP1B-mediated inhibition of insulin signaling, resulting in decreased HGP. To achieve this, we used the PTP1B inhibitor claramine (Han et al., 2008) to repeat the protocol of i.c.v. injection followed by clamps as we previously used with LAN injections. The central inhibition of PTP1B was associated with a decrease in HGP (Figures 2D and S2B) and an increase in GIR during the clamp (Figures 2A and 2C) . Notably, the improvement in the suppression of HGP was similar to the LAN group and there was no additive effect when both LAN and claramine were co-injected (Figures 2A-2E ). Body weights did not vary among the treatment groups (Figure S2A ). Importantly, LAN treatment normalized the elevated expression of PTP1B observed in the mediobasal hypothalamus (MBH) of DIO mice ( Figure 2F ). In addition, the increase in hepatic gluconeogenic genes mRNA levels in DIO mice, namely Pck1 and G6pc, was completely abolished following LAN treatment ( Figures 2G and 2H ). These results suggest that the attenuation of insulin signaling caused by central LepRb signaling is mediated through the induction of PTP1B in DIO mice.
To further evaluate the role of PTP1B in ARH insulin resistance, we fed Ptpn1 fl/fl mice a high fat diet (HFD) for 20 weeks and then performed intra-ARH rAAV-cytomegalovirus (CMV)-Cre-GFP injections to specifically ablate PTP1B in ARH neurons of DIO mice 4 weeks before clamp studies. As experimental controls, we included a small number of mice with control adeno-associated virus (AAV)-GFP virus injections. Post mortem anatomical GFP expression analyses were performed for each mouse to determine successful recombination in the ARH. Specifically, Ptpn1 fl/fl mice were categorized into either AAV-Cre ''missed'' or AAV-Cre ''hit'' group by the absence or presence of GFP expression in the ARH ( Figures 3A and S3 ). Of note, Ptpn1 fl/fl mice were obese at the time of virus injection ( Figure 3B ; two-way ANOVA: time: p = 0.87; injection site: p = 0.18; interaction: p = 0.98; n = 7 or 8 mice/group), and the body weight between the two groups (hit and missed) did not vary 4 weeks after intra-ARH injection ( Figure 3C ; two-tailed unpaired t test: p = 0.3; n = 7 or 8 mice/ group). In agreement with our pharmacological studies, AAV-Cre hit mice displayed a marked elevation in GIR and a significant reduction in HGP compared to the AAV-Cre missed and the AAV-GFP control groups (Figures 3D-3G and S2D). As before, GDR remained unchanged across all the groups (Figure 3H ). Furthermore, deleting PTP1B in the ARH restored insulin's capacity to suppress HGP in obese mice, and these results were independent of any changes in body weight ( Figure S2C ).
PTP1B in AgRP Neurons Modulates Insulin Signaling and Glucose Homeostasis
AgRP neurons constitute a major ARH neuronal population that expresses high levels of LepRb and InsR. Accordingly, we hypothesized that leptin might influence the insulin response primarily in AgRP neurons. Therefore, we bred Ptpn1 fl/fl (C57BL/6) mice (Bence et al., 2006) with Agrp-Ires-Cre mice (Tong et al., 2008) to delete PTP1B specifically in AgRP neurons (AgRP-1B mice). Of note, PTP1B expression was not affected in peripheral tissues involved in glucose homeostasis and in germline cells of AgRP-1B mice ( Figures S4H-S4J ). On chow diet, AgRP-1B mice displayed similar body weights, body composition, adipose tissue weights (Figures 4H, S4A , and S4B), and energy expenditure ( Figure S4E ) to control Ptpn1 fl/fl mice, despite having lower food intake and respiratory exchange ratio (RER) ( Figures S4C, S4D , and S4G). Strikingly, AgRP-1B mice displayed a greater sensitivity to insulin when compared to control mice as indicated by elevated insulin-induced Akt phosphorylation (pAkt) in the ARH ( Figures 4A and 4B) . Additionally, AgRP-1B mice had lower blood glucose levels in the fasted state ( Figure 4C ) and increased tolerance to exogenous glucose and insulin ( Figures 4D-4G ). Importantly, these differences were independent of changes in energy expenditure, oxygen consumption and RER ( Figures  S4E-S4G ). Upon high-fat feeding, AgRP-1B mice developed diet-induced obesity but gained significantly lower body weight compared to their Ptpn1 fl/fl littermates after 16 weeks of HFD ( Figure 4H ). The differences in body weight and insulin sensitivity between Ptpn1 fl/fl and AgRP-1B mice would confound the interpretation of hyperinsulinemic-euglycemic clamps as we All data are represented as mean ± SEM. ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 as determined by one-way ANOVA followed by Tukey's post hoc test (C: n = 5-10 mice/group; F: n = 6-7 mice/group; G and H: n = 3-4 mice/group) and two-way ANOVA followed by Bonferroni's post hoc test (D and E: n = 5-10 mice/group). See also Figure S2 . (legend continued on next page) had previously performed in this series of studies. Therefore, to investigate the contribution of HGP regulation in the improved glucose homeostasis of AgRP-1B/HFD mice despite body weight (BW) difference between groups, we performed a pyruvate tolerance test in AgRP-1B/HFD and Ptpn1 fl/fl /HFD mice. High-fat-fed AgRP-1B mice had a markedly improved tolerance to pyruvate relative to their Ptpn1 fl/fl /HFD littermates. In line with our clamp studies, 3 days of LAN i.c.v. injection improved pyruvate tolerance in Ptpn1 fl/fl /HFD mice, matching AgRP-1B/HFD mice response to pyruvate. Noteworthy, there was no further improvement of pyruvate tolerance in response to LAN treatment in AgRP-1B/HFD mice ( Figures 4I and 4J) . These findings are consistent with the leptin-induced repression of insulin signaling in AgRP neurons and the promotion of HGP in DIO mice due to the induction of PTP1B in AgRP neurons.
DISCUSSION
The failure of exogenous leptin to reduce appetite and to cause weight loss in obese subjects has led to the concept of leptin resistance. In the current study, we sought to re-assess leptin resistance in the hypothalamus and its influence on glucose homeostasis in obesity. Our results demonstrate that the activation of leptin signaling in ARH is responsible, at least in part, for the uncontrolled hepatic glucose production (HPG) causing impaired blood glucose regulation in obesity.
Recently, Ottaway and colleagues (Ottaway et al., 2015) demonstrated that endogenous leptin still regulates energy homeostasis in DIO mice. They showed that pegylated-LAN treatment increased food intake and body weight similarly in control and DIO mice, demonstrating that endogenous leptin activity is still present in DIO mice (Ottaway et al., 2015) . In our study, we showed that the use of non-pegylated LAN (shorter bioactivity) did not affect feeding and body weight of control and DIO mice, thereby eliminating confounding factors, which could modify the response to hyperinsulinemic-euglycemic clamps.
Leptin and insulin share neuronal targets in the brain (Belgardt and Br€ uning, 2010) , and a substantial body of evidence shows they both have crucial roles in regulating energy balance (Br€ uning et al., 2000; Dodd et al., 2015; Halaas et al., 1995; Woods et al., 1979) and glucose homeostasis (Berglund et al., 2012; Fujikawa et al., 2013; Hill et al., 2010; Obici et al., 2002; Pocai et al., 2005b) . A recent study has reported that at least 50% of arcuate LepR-expressing neurons were also responsive to central administration of insulin (Garcia-Galiano et al., 2017), and previous work from our group demonstrated the physiological importance of leptin and insulin co-action on ARH neurons to regulate energy balance . The existence of a cross-talk between leptin and insulin signaling in ARH neurons led us to hypothesize that hyperleptinemia in DIO mice could lead to an imbalance between leptin and insulin signaling in ARH neurons and consequently impair the regulation of glucose homeostasis in obesity.
Hypothalamic insulin resistance has been reported in obese humans (Heni et al., 2014 (Heni et al., , 2015 . Intranasal insulin administration is known to suppress endogenous glucose production in lean men. However, in overweight or obese insulin-resistant men, the same dose of intranasal insulin was ineffective during a pancreatic clamp (Xiao et al., 2018) . In rodents, the inhibition of central InsR signaling induces hyperglycemia and glucose intolerance (Vikram and Jena, 2010) . Central insulin signaling is known to control HGP (Obici et al., 2002) via the vagus nerve (Kimura et al., 2016; Vikram and Jena, 2010) in rodents. Our studies reaffirm the importance of central InsR signaling. The restored suppression of HGP induced by i.c.v. LAN in DIO mice was lost when central insulin receptor was blocked with the specific InsR antagonist, S961, demonstrating that the control of HGP relies largely on functional insulin signaling in the CNS of DIO mice. Given the modest reduction in GDR after i.c.v. S961 in DIO mice, this highlights the involvement of central InsR signaling in regulating insulin sensitivity in other peripheral tissues. In fact, mice with specific InsR ablation in NPY neurons display a significant decrease in glucose uptake into skeletal muscle during clamp (Loh et al., 2017) . These studies all point to the notion that alterations in ARH insulin signaling are involved in the perturbation of systemic glucose homeostasis associated with obesity. Although the central effect of insulin on HGP does not appear to extend to dogs (Ramnanan et al., 2013) , a recent study has utilized fMRI and hyperinsulinemic-euglycemic clamps to show that intranasal insulin acts on the hypothalamus to inhibit endogenous glucose production in humans (Heni et al., 2017) . Thus, we propose that, in obese individuals, hyperleptinemia might constantly drive LepRb signaling to concurrently impede insulin action on neurons involved in glucose homeostasis. We used an in vivo approach to corroborate findings from previous studies, which reported that intact insulin signaling in the ARH is required to regulate HGP (Kimura et al., 2016; Obici et al., 2002) . Indeed, LAN treatment restored hepatic insulin sensitivity and pyruvate tolerance in DIO mice. Further, we also showed that central blockade of InsR exacerbated the insulin-resistant state in DIO mice.
The central action of leptin on glucose homeostasis is highlighted in our clamp studies performed in lean mice with LepRb (legend continued on next page) inhibition. These mice displayed a severe impairment in wholebody glucose homeostasis, as evidenced by reduced GIR and GDR and increased HGP. These findings show that, under normal conditions, intact central leptin signaling is critical in regulating glucose homeostasis. Indeed, previous work from Rossetti's group has described the role of leptin in mediating hepatic glucose fluxes through melanocortin-dependent and melanocortin-independent pathways (Gutié rrez-Juá rez et al., 2004) . Hence, it may be expected that the presence of excessive leptin levels in obese mice might similarly alter the regulation of HGP. In the current study, obese mice display increased body weight and elevated HGP associated with impaired leptin and insulin action. Specifically, when central insulin fails to regulate blood glucose, the blockade of leptin signaling in the brain is capable of restoring insulin signaling in the ARH to suppress HGP in DIO mice.
In obese mice, hyperleptinemia in the ARH increases the expression of SOCS3 (Bjørbaek et al., 1998; M€ unzberg et al., 2004) , PTP1B (Elchebly et al., 1999; Klaman et al., 2000; Zabolotny et al., 2002) , and TCPTP (Loh et al., 2011) . Normally, these regulators exert a negative feedback upon activation of the LepRb-signaling cascade. This notion is supported by a significant reduction in SOCS3 mRNA levels in DIO mice with chronic LAN treatment (Ottaway et al., 2015) and the enhanced leptin signaling and sensitivity accompanying PTP1B and TCPTP deletion in the CNS (Bence et al., 2006; Loh et al., 2011) .
Our data suggest a cross-talk between leptin and insulin signaling whereby leptin signaling inhibits insulin signaling, leading to impaired glucose homeostasis in DIO. This notion is supported by a recent study showing that SOCS3 inactivation in LepRb-expressing neurons protected mice from diet-induced insulin resistance independently of body weight (Pedroso et al., 2014) . PTP1B is another leptin-induced negative feedback molecule (Zabolotny et al., 2002) , and it is a potent negative regulator of insulin signaling dephosphorylating the insulin receptor and insulin receptor substrate-1 (Elchebly et al., 1999; Galic et al., 2005; Goldstein et al., 1998; Zhang et al., 2015) . PTP1B also represses leptin signaling (Bence et al., 2006; Zabolotny et al., 2002; Zhang et al., 2015) , and mice lacking PTP1B in lepRbexpressing neurons are hypersensitive to leptin and resistant to high-fat feeding (Tsou et al., 2012) . Moreover, high-fat-fed mice with neuronal deletion of PTP1B display increased insulin sensitivity and improved glucose tolerance (Bence et al., 2006) .
Because leptin and insulin-responsive neurons in the ARH can overlap Garcia-Galiano et al., 2017) , hyperleptinemia-induced leptin signaling could result in sustained PTP1B activity to blunt insulin signaling in the ARH neurons of DIO mice. We investigated the role of PTP1B in ARH neurons to determine how LepRb signaling may contribute to hypothalamic insulin resistance in DIO mice. We found that the central inhibition of PTP1B in DIO mice restored hypothalamic insulin signaling and the suppression of HGP during hyperinsulinemic-euglycemic clamps. Importantly, the degree of restoration of hypothalamic insulin signaling was similar between the central inhibition of PTP1B and the blockade of leptin signaling with LAN. It remains tempting to postulate that the increase in PTP1B protein as a consequence of hyperleptinemia perturbs insulin-mediated control of HGP in DIO mice through the melanocortin-independent pathway described by Rossetti and colleagues (Gutié rrez-Juá rez et al., 2004) . Furthermore, we employed temporal ARH-targeted PTP1B deletion after the onset of obesity to discriminate between effects in the ARH versus the whole-brain inhibition of phosphatase. Specifically, we found that our control (AAV-Cre missed) mice remained insulin resistant, and mice with successful Cre-mediated recombination (AAV-Cre hit) in the ARH displayed a similar improvement in hepatic insulin sensitivity to that achieved with pharmacological LAN inhibition. Thus, we propose that obesity-induced hyperleptinemia causes persistent leptin signaling and thereby increases PTP1B protein in ARH neurons to repress insulin signaling, so that insulin fails to appropriately suppress HGP, thereby contributing to hyperglycemia in obesity.
To date, AgRP and proopiomelanocortin (POMC) neurons have been largely implicated in the regulation of glucose homeostasis, given that they express high levels of LepRb and InsR (Belgardt and Br€ uning, 2010) . Preliminary studies of insulin signaling in POMC and AgRP neurons by immunohistochemistry suggested that insulin response specifically in AgRP neurons could be altered by high leptin levels (data not shown).
Building on this notion, we generated mice with PTP1B deletion only in AgRP neurons (AgRP-1B). Interestingly, AgRP-1B mice displayed improved glucose tolerance and insulin sensitivity, in accordance with our in vivo pharmacological inhibition and ARH genetic deletion studies. Noteworthy, AgRP-1B mice retain the capacity to control HGP, even in the obese state. This illustrates the involvement of AgRP neurons in the mechanisms of hypothalamic insulin resistance linked to obesity and the associated hyperglycemia. In line with this notion, overexpressing PTP1B specifically in AgRP neurons may cause uncontrolled HGP and ultimately lead to hyperglycemia.
In conclusion, our study indicates that leptin signaling persists in ARH neurons in obesity, which impairs insulin action in AgRP neurons through the induction of PTP1B. Our findings demonstrate that pathological leptin signaling in the ARH underpins the alteration of hypothalamic insulin signaling, and it accounts, at least in part, for the failure of insulin action in the hypothalamus-liver axis, which suppresses HGP, leading to the perturbation of glucose homeostasis in obesity.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: d KEY RESOURCES TABLE d CONTACT FOR REAGENT AND RESOURCE SHARING All data are represented as mean ± SEM. ns, p > 0.05; *p < 0.05; **p < 0.01; as determined by one-way ANOVA followed by Tukey's post hoc test (J: n = 6-8 mice/ group), two-way ANOVA followed by Tukey's post hoc test (B: n = 4 mice/group; C: n = 10-11 mice/group), two-tailed unpaired t test (E and G: n = 10-11 mice/ group), and two-way ANOVA with repeated measures (H: n = 9-12 mice/group; interaction: ****p < 0.0001; time: ****p < 0.0001; genotype: *p < 0.05). See also Figure S4 . 
STAR+METHODS KEY RESOURCES TABLE
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Michael Cowley (michael.cowley@monash.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All animal procedures were approved by Monash University Animal Ethics Committee. Two-to three-month-old male C57BL6 mice (Monash Animal Services) were housed in a controlled environment with constant temperature and 12hr light/12hr dark cycle in a high-barrier facility (Monash ARL). Mice were either fed ad libitum with standard chow diet (8.5% fat, Barastoc, Ridley AgriProducts, Australia) or HFD (43% energy from fat, SF04-001, Specialty Feeds, Western Australia, Australia) for 12 to 20 weeks. To generate Agrp-Ires-Cre; Ptpn1 fl/fl (AgRP-1B), Ptpn1 fl/fl (C57BL/6) mice (Bence et al., 2006) were bred with Agrp-Ires-Cre mice (Tong et al., 2008) .
METHOD DETAILS Genotyping
Genotyping was performed by PCR on DNA extracted from tail biopsies using primers previously described for the Agrp-Ires-Cre (Tong et al., 2008) and Ptpn1 fl/fl mice (Bence et al., 2006) . REAGENT 
